Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a high risk of morbidity and mortality; however, there is no cure and the current medications are far from optimal in addressing efficacy and safety concerns. Over the past decade, various emerging technologies have been used in the search for novel drug targets of SLE which have resulted in numerous promising data. However, the systematic review and careful digestion of this information have been lacking. Areas covered: In this review, the authors summarize promising biomarkers and drug targets which have been identified via various multiplexing and high-throughput proteomic strategies. The authors also introduce emerging technologies which are hopeful to be used for the discovery of novel biomarkers and therapeutic targets of SLE in the near future. Expert opinion: Emerging proteomic technologies and genome-wide association studies (GWAS) have been the new driving forces in the discovery of novel biomarkers and promising therapeutic targets of SLE. Careful validation of these potential targets in lupus mouse models and clinical trials are urgently needed so that the next generation of target-specific medications can be developed for SLE patients.
Keywords: Aptamer; biomarker; drug target; lupus; proteomics.